SCHEMBL6042876

SCHEMBL6042876

CSc1ccc(COC2CN(C(=O)O)CCC2c2ccc(O)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.38
SLC6A2 P23975 3/20 0.36
SLC6A4 P31645 3/20 0.36
SLC6A3 Q01959 3/20 0.36
KDM4E B2RXH2 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ATM Q13315 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 2/20 0.35
GAA P10253 2/20 0.35
MAPT P10636 2/20 0.35
SIGMAR1 Q99720 1/20 0.35
AXL P30530 1/20 0.35
MERTK Q12866 1/20 0.35
LMNA P02545 1/20 0.34
GFER P55789 1/20 0.34
ADRB2 P07550 1/20 0.34
REN P00797 1/20 0.34
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6041697 0.92 MEN1 (0.39) GPR119MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6950785 0.86 SLC6A2 (0.37) GPR119SLC6A2SLC6A4SLC6A3KDM4E
SCHEMBL6043843 0.86 SLC6A2 (0.39) SLC6A2SLC6A4SLC6A3KDM4ESMN1; SMN2
SCHEMBL6041647 0.82 PPARG (0.39) MEN1KMT2ALMNAREN
SCHEMBL6041822 0.82 REN (0.49) KDM4EALDH1A1LMNARENKCNH2
SCHEMBL6041640 0.82 PPARG (0.39) MEN1KMT2ALMNAREN
SCHEMBL6960968 0.80 GPR119 (0.40) GPR119SLC6A2SLC6A4SLC6A3MEN1
SCHEMBL6042287 0.80 REN (0.52) REN
SCHEMBL6043886 0.80 REN (0.39) REN
SCHEMBL6043165 0.79 REN (0.46) MEN1KMT2ASMN1; SMN2ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079533-A1 Methods of treating alzheimer's disease NIEMAN JAMES A 2006-04-13 US disclosed
EP-0863875-B1 NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY HOFFMANN LA ROCHE (CH) 2003-06-04 EP disclosed
WO-2002076440-A2 METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES ELAN PHARMACEUTICALS, INC. (US) 2002-10-03 WO disclosed
US-6150526-A Piperidine derivative having renin inhibiting activity HOFFMANN-LA ROCHE INC. (US) 2000-11-21 US disclosed
US-6051712-A PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS HOFFMANN-LA ROCHE INC. (US) 2000-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079533-A1 Methods of treating alzheimer's disease BACE1, PSEN1, PSEN2 GPR119 856/4885SLC6A2 3109/4885SLC6A4 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.